Tandem Diabetes Care

Last updated
Tandem Diabetes Care, Inc.
Company type Public
Founded2006;18 years ago (2006), in San Diego, California
Headquarters
San Diego, California
,
U.S.
Key people
Kim Blickenstaff (executive chairman)
John F. Sheridan (president and CEO)
RevenueIncrease2.svg US$362 million (2019) [1]
Increase2.svg US$183.4 million (2018)
Number of employees
1,500 (2020)
Website tandemdiabetes.com

Tandem Diabetes Care, Inc. is an American medical device manufacturer based in San Diego, California. The company develops medical technologies for the treatment of diabetes and specifically insulin infusion therapy. [2]

Contents

History

In 2006, a group of engineers recognized the need for new and improved methods of pumping insulin and incorporated as Phluid, Inc. [3] In 2007, Kim Blickenstaff joined the organization as president and CEO, bringing his philosophy of using market research as the inspiration for product development and started on the development of the t:slim Insulin Pump. [4] In 2008, this predecessor company became the newly incorporated Tandem Diabetes Care, Inc. that was formed with a focus on promoting a comprehensive, user-centric, and integrated approach to diabetes product development and customer care. [5] Tandem Diabetes Care felt that incorporating enhanced ease of use and attractive design—often associated with consumer electronics development—would also encourage more patients to consider the clinical benefits of insulin pump therapy. Tandem Diabetes Care interviewed more than 4,000 insulin pump users and health care providers to design its first device, the t:slim Insulin Pump. [6]

In 2016, the company was ranked #39 on the Deloitte Fast 500 North America list. [7]

In 2018, the company was recognized as a top workplace in San Diego by the San Diego Union-Tribune. [8]

In February 2019, the company announced that CEO Kim Blickenstaff would transition to a newly created position of Executive Chairman of the board of directors. John F. Sheridan (previously COO) will succeed Mr. Blickenstaff, assuming the role of President and CEO effective March 1, 2019. [9]

Products

In November 2011, the company received FDA clearance to market the t:slim Insulin Pump, the first ever touch-screen insulin pump. [10] In February 2013, the company received FDA clearance to market the t:connect Diabetes Management Application, a Mac and PC-compatible data management application that provides t:slim Pump users and their healthcare providers a way to display data from the pump and supported blood glucose meters on a cloud-based platform.[ citation needed ] In January 2015, Tandem announced FDA clearance of the t:flex Insulin Pump, which was the largest capacity insulin pump on the market.[ citation needed ] In July 2014, Tandem announced that it had submitted a PMA for the t:slim G4 insulin pump, which integrated t:slim Pump technology with the Dexcom G4 Platinum CGM System. This device was approved by the FDA in September 2015. [11] The FDA approved a tool to update the software on Tandem's pumps in July 2016. The Tandem Device Updater would be used to deliver all software updates to Tandem's pumps moving forward and that the first use of the new tool will be to update t:slim pumps which were shipped prior to April 2015 with a new version of the firmware which speeds the loading process and offers other enhancements. [12] In late October 2016, Tandem began shipping its next-generation pump platform, the t:slim X2. [13]

In August 2017, Tandem launched its t:lock Connector. In the same month, it announced the launch of the t:slim X2 Insulin Pump with Dexcom G5 Mobile CGM. In July 2018, the company launched its first automated insulin delivery (AID) algorithm, with the t:slim X2 Insulin Pump with Basal-IQ predictive low glucose suspend Technology, and in February 2019, the FDA classified the t:slim X2 insulin pump as the first in a new device category called Alternate Controller Enabled Infusion Pumps (ACE pumps). [14]

The t:slim X2 pump will continue to receive updates via the Tandem Device Updater, with a planned update including the Control-IQ hybrid closed-loop algorithm (licensed from TypeZero in July 2016) available beginning in January 2020. [15]

Related Research Articles

<span class="mw-page-title-main">Insulin pump</span> Medical device to administer insulin

An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy. The device configuration may vary depending on design. A traditional pump includes:

<span class="mw-page-title-main">Blood glucose monitoring</span> Use of a glucose monitor for testing the concentration of glucose in the blood

Blood glucose monitoring is the use of a glucose meter for testing the concentration of glucose in the blood (glycemia). Particularly important in diabetes management, a blood glucose test is typically performed by piercing the skin to draw blood, then applying the blood to a chemically active disposable 'test-strip'. The other main option is continuous glucose monitoring (CGM). Different manufacturers use different technology, but most systems measure an electrical characteristic and use this to determine the glucose level in the blood. Skin-prick methods measure capillary blood glucose, whereas CGM correlates interstitial fluid glucose level to blood glucose level. Measurements may occur after fasting or at random nonfasting intervals, each of which informs diagnosis or monitoring in different ways.

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Green Oaks, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

<span class="mw-page-title-main">Medtronic</span> Irish tax-registered medical device company

Medtronic plc is an American company based in Ireland for tax purposes. The company's operational and executive headquarters are in Minneapolis, Minnesota, and its legal headquarters are in Ireland due to its acquisition of Irish-based Covidien in 2015. While it primarily operates in the United States, it operates in more than 150 countries and employs over 90,000 people. It develops and manufactures healthcare technologies and therapies.

<span class="mw-page-title-main">Glucose meter</span> Medical device for determining the concentration of glucose in the blood

A glucose meter, also referred to as a "glucometer", is a medical device for determining the approximate concentration of glucose in the blood. It can also be a strip of glucose paper dipped into a substance and measured to the glucose chart. It is a key element of glucose testing, including home blood glucose monitoring (HBGM) performed by people with diabetes mellitus or hypoglycemia. A small drop of blood, obtained from slightly piercing a fingertip with a lancet, is placed on a disposable test strip that the meter reads and uses to calculate the blood glucose level. The meter then displays the level in units of mg/dL or mmol/L.

JDRF is a nonprofit 501(c)(3) organization that funds type 1 diabetes (T1D) research, provides a broad array of community and activist services to the T1D population and actively advocates for regulation favorable to medical research and approval of new and improved treatment modalities. It was initially founded as the JDF, the Juvenile Diabetes Foundation. It later changed its name to the Juvenile Diabetes Research Foundation and is now known as JDRF.

<span class="mw-page-title-main">Inhalable insulin</span> Powdered insulin delivered with an inhaler

Inhalable insulin is a powdered form of insulin, delivered with an inhaler into the lungs where it is absorbed. In general inhaled insulins have been more rapidly absorbed than subcutaneous injected insulin, with faster peak concentration in serum and more rapid metabolism.

Automated insulin delivery systems are automated systems designed to assist people with insulin-requiring diabetes, by automatically adjusting insulin delivery in response to blood glucose levels. Currently available systems can only deliver a single hormone—insulin. Other systems currently in development aim to improve on current systems by adding one or more additional hormones that can be delivered as needed, providing something closer to the endocrine functionality of the pancreas.

LifeScan, Inc. is a diagnostic systems manufacturer with products focusing on the diabetes market, specifically blood glucose monitoring systems.

<span class="mw-page-title-main">Amylin Pharmaceuticals</span> Biopharmaceutical company

Amylin Pharmaceuticals, Inc. is a biopharmaceutical founded in 1987 that was based in San Diego, California. The company was engaged in the discovery, development, and commercialization of drug candidates for the treatment of diabetes, obesity, and other diseases. Amylin produced three drugs: Symlin, Byetta (exenatide) and Bydureon.

Noninvasive glucose monitoring (NIGM), called Noninvasive continuous glucose monitoring when used as a CGM technique, is the measurement of blood glucose levels, required by people with diabetes to prevent both chronic and acute complications from the disease, without drawing blood, puncturing the skin, or causing pain or trauma. The search for a successful technique began about 1975 and has continued to the present without a clinically or commercially viable product.

<span class="mw-page-title-main">Minimed Paradigm</span> Insulin pumps

MiniMed Paradigm is a series of insulin pumps manufactured by Medtronic for patients with diabetes mellitus. The pump operates with a single AAA battery and uses a piston-plunger pump to infuse a programmed amount of insulin into the patient through a length of tubing. The Paradigm uses a one-way wireless radio frequency link to receive blood sugar measurements from select glucose meters. The Paradigm RT series adds the ability to receive data from a mated continuous blood-glucose monitor. Although the pump can use these measurements to assist in calculating a dose of insulin, no actual change in insulin delivery occurs without manual user-intervention.

DexCom, Inc. is a company that develops, manufactures, produces, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has manufacturing facilities in Mesa, Arizona and Batu Kawan, Malaysia.

D. Medical Industries is a publicly traded holding company, headquartered in Israel, that develops and markets insulin pumps and infusion sets through its subsidiary, Spring-Set Health Solutions. Shares of the company are traded on the Tel Aviv Stock Exchange.

<span class="mw-page-title-main">Alere</span> Subsidiary of Abbott

Alere Inc. was a global manufacturer of rapid point-of-care diagnostic tests. The company was founded in 1991 and was headquartered in Waltham, Massachusetts. As of January 2017, the company had a market capitalization of $3.47 billion with an enterprise value of $5.9 billion. The company was formerly known as Inverness Medical Innovations, Inc. and changed its name to Alere Inc. in 2010.

<span class="mw-page-title-main">Verily</span> Life sciences research organization

Verily Life Sciences LLC, also known as Verily, is Alphabet Inc.'s research organization devoted to the study of life sciences. The organization was formerly a division of Google X, until August 10, 2015, when Sergey Brin announced that the organization would become an independent subsidiary of Alphabet Inc. with restructuring completed on October 2, 2015. On December 7, 2015, Google Life Sciences was renamed Verily.

Ambulatory glucose profile (AGP) is a single-page, standardized report for interpreting a patient's daily glucose and insulin patterns. AGP provides both graphic and quantitative characterizations of daily glucose patterns. First developed by Drs. Roger Mazze and David Rodbard, with colleagues at the Albert Einstein College of Medicine in 1987, AGP was initially used for the representation of episodic self-monitored blood glucose (SMBG). The first version included a glucose median and inter-quartile ranges graphed as a 24-hour day. Dr. Mazze brought the original AGP to the International Diabetes Center (IDC) in the late 1980s. Since then, IDC has built the AGP into the internationally recognized standard for glucose pattern reporting.

Nightscout is a free and open-source project, and associated social movement, that enables accessing and working with continuous glucose monitor (CGM) data. Nightscout software aims to give users access to their real time blood sugar data by putting this data in the cloud. In addition to browser-based data visualization, Nightscout can also be used to review data from a phone or smartwatch, or to remotely monitor CGM data for individuals with type 1 diabetes. Associated with Nightscout software is a broader "CGM in the Cloud" social movement, supporting individuals seeking to access and use realtime CGM data through commercial and DIY approaches.

The Open Artificial Pancreas System (OpenAPS) project is a free and open-source project that aims to make basic artificial pancreas system (APS) technology available to everyone. The OpenAPS project was designed with the idea of quickly getting the APS technology to more people using a direct approach, rather than waiting for clinical trials to be completed and regulatory approval to be granted.

<span class="mw-page-title-main">Continuous glucose monitor</span> Blood glucose monitoring device

A continuous glucose monitor (CGM) is a device used for monitoring blood glucose on a continual basis instead of monitoring glucose levels periodically by drawing a drop of blood from a finger. This is known as continuous glucose monitoring. CGMs are used by people who treat their diabetes with insulin, for example people with type 1 diabetes, type 2 diabetes, or other types of diabetes, such as gestational diabetes.

References

  1. ↑ "Tandem Diabetes Care Revenue 2012-2021 | TNDM".
  2. ↑ "Stocks". Archived from the original on September 6, 2013.
  3. ↑ "TNDM: Tandem Diabetes Care Inc Stock Price Quote - NASDAQ GM - Bloomberg". Bloomberg News .
  4. ↑ "San Diego's Tandem Diabetes to sell compact insulin pump". San Diego Union-Tribune. November 16, 2011.
  5. ↑ "Archived copy". Archived from the original on 2015-04-02. Retrieved 2015-03-30.{{cite web}}: CS1 maint: archived copy as title (link)
  6. ↑ "Tandem Diabetes Care".
  7. ↑ "2016 Winners by rank" (PDF). Deloitte . Retrieved 29 October 2017.
  8. ↑ "Tandem Diabetes Care Honored in San Diego 2018 Top Workplaces Awards From San Diego Union-Tribune".
  9. ↑ "Tandem Diabetes Care Announces Succession Plan for Chief Executive Officer and Board of Directors". 26 February 2019.
  10. ↑ "Tandem t:slim Insulin Pump Gets FDA Clearance | Medgadget".
  11. ↑ "FDA Approves New Insulin Pump-Continuous Sensor Combo".
  12. ↑ "Tandem Diabetes Care Announces FDA Clearance of Remote Software Update Tool for Insulin Pumps | Tandem Diabetes Care".
  13. ↑ "Tandem Diabetes Care Now Shipping Next-Generation t:slim X2 Insulin Pump". 24 October 2016.
  14. ↑ "T:slim X2 Insulin Pump First to Receive New ACE Pump Classification by FDA | Tandem Diabetes Care".
  15. ↑ "Tandem Diabetes Care Announces FDA Clearance of the t:slim X2 Insulin Pump with Control-IQ Advanced Hybrid Closed-Loop Technology". 13 December 2019.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.